MedTrace Logo

Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo

NCT02097147 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2015-02-12

No results posted yet for this study

Summary

To compare the effects of vilazodone, paroxetine and placebo on sexual function in sexually active healthy adults.

Conditions

  • Healthy

Interventions

DRUG

Vilazodone 20 mg

Oral administration, once per day.

DRUG

Vilazodone 40 mg

Oral administration, once per day.

DRUG

Paroxetine 20 mg

Oral administration, once per day.

DRUG

Placebo

Oral administration, once per day.

Sponsors & Collaborators

  • Forest Laboratories

    lead INDUSTRY

Principal Investigators

  • Maju Mathews, MD · Forest Laboratories

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-09-30
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02097147 on ClinicalTrials.gov